Anti-Nicastrin Antibody (A5226A) 

Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease^[1][2][3].

Human

Anti-Nicastrin Antibody (A5226A) binds to human NCT at epitope R391, and interacts with both mature (active γ-secretase complex-associated) and immature forms of human NCT in NKO cells overexpressing human NCT^[1].
Anti-Nicastrin Antibody (A5226A) specifically recognizes active γ-secretase complexes containing mature NCT localized in CTB-positive lipid raft microdomains on the plasma membrane of HeLa cells and NKO cells expressing human NCT^[1].
Anti-Nicastrin Antibody (A5226A) dose-dependently inhibits γ-secretase activity in HEK293 cells stably expressing amyloid precursor protein- or Notch-derived γ-secretase substrates^[1].
Anti-Nicastrin Antibody (A5226A) inhibits γ-secretase activity in a cell-free in vitro assay by interfering with the interaction between NCT and Notch-based substrate N100^[1].
Anti-Nicastrin Antibody (A5226A) inhibits γ-secretase-dependent proliferation of A549 non-small cell lung cancer cells and DND-41 T-cell acute lymphoblastic leukemia cells, but does not affect HeLa cell viability^[1].
Anti-Nicastrin Antibody (A5226A) inhibits γ-secretase activity via substrate competition in cell-free assays and causes a moderate decrease in ICN1 in DND41 T-ALL cells in vitro^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Nicastrin Antibody (A5226A) (50 mg/kg; i.p.; every 4-5 days; at least 30 days) inhibits γ-secretase activity-dependent cancer cell growth in vivo, achieving a 55.2% reduction in tumor volume at day 38 in a DND-41 xenograft model^[1].
Anti-Nicastrin Antibody (A5226A) produces a significant reduction in tumor volume in human DND41 T-ALL xenotransplant models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

23385  [NCBI]

Q92542

Nicastrin

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hayashi I, et al. Neutralization of the γ-secretase activity by monoclonal antibody against extracellular domain of nicastrin. Oncogene. 2012;31(6):787-798.

  [2]. Kanatsu K, et al. Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase. Nat Commun. 2014;5:3386. Published 2014 Feb 28.

  [3]. Roti G, et al. New Approaches to Target T-ALL. Front Oncol. 2014;4:170. Published 2014 Jul 8.